Courtney Rehak

Statistics

Publications

Citations

712

H-Index

Active since

2014

Affiliations

Cognition Therapeutics (United States)(Current)

University of Kentucky

Washington University in St. Louis

Columbia University

University of Edinburgh

Courtney Rehak is an author at Cognition Therapeutics (United States) specializing in neurodegenerative disorders, neuroscience, and neurodegenerative diseases.

ORCID

Publications per year

2014–2021

Publications

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Nicholas J. Izzo, Jinbin Xu, Chenbo Zeng et al. · PLoS ONE · 2014 · 303 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Nicholas J. Izzo, Agnes Staniszewski, Lillian K. To et al. · PLoS ONE · 2014 · 187 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera et al. · Alzheimer s & Dementia · 2021 · 103 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease

Gilbert M. Rishton, Gary C. Look, Zhi‐Jie Ni et al. · ACS Medicinal Chemistry Letters · 2021 · 41 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein

Colleen S. Limegrover, Raymond Yurko, Nicholas J. Izzo et al. · Journal of Neuroscience Research · 2021 · 40 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

1–5 of 7